Altimmune Announces Second Quarter 2022 Financial Results and Provides a Business Update
August 11, 2022 07:00 ET
|
Altimmune, Inc
GAITHERSBURG, Md., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and six months ended...
Altimmune to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11
August 04, 2022 07:30 ET
|
Altimmune, Inc
GAITHERSBURG, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2022 financial...
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress™ on June 25, 2022
June 17, 2022 07:30 ET
|
Altimmune, Inc
GAITHERSBURG, Md., June 17, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Medical Director,...
Altimmune to Participate at Two Upcoming Investor Conferences
June 03, 2022 07:30 ET
|
Altimmune, Inc
GAITHERSBURG, Md., June 03, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will...
Altimmune to Present Pemvidutide Clinical Data at Upcoming American Diabetes Association Scientific Sessions June 6, 2022
May 31, 2022 07:30 ET
|
Altimmune, Inc
GAITHERSBURG, Md., May 31, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Samuel Klein, William H. Danforth Professor of...
Altimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022
May 20, 2022 07:30 ET
|
Altimmune, Inc
GAITHERSBURG, Md., May 20, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at...
Altimmune to Present at Upcoming Investor Conferences
May 16, 2022 07:30 ET
|
Altimmune, Inc
GAITHERSBURG, Md., May 16, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will...
Altimmune Announces First Quarter 2022 Financial Results and Provides a Corporate Update
May 12, 2022 07:00 ET
|
Altimmune, Inc
GAITHERSBURG, Md., May 12, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended March 31,...
Altimmune to Report First Quarter 2022 Financial Results and Provide Business Update on May 12
May 05, 2022 07:30 ET
|
Altimmune, Inc
GAITHERSBURG, Md., May 05, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2022 financial...
Altimmune Announces Initiation of 48-week Phase 2 MOMENTUM Trial of Pemvidutide in Obesity
April 01, 2022 07:00 ET
|
Altimmune, Inc
GAITHERSBURG, Md., April 01, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first subject in the 48-week...